trending Market Intelligence /marketintelligence/en/news-insights/trending/trms8cG9b5JaeV5Tgcqwvg2 content esgSubNav
In This List

Global Blood Therapeutics plans $100M common stock offering

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Global Blood Therapeutics plans $100M common stock offering

Global Blood Therapeutics Inc. plans to sell $100 million of common stock in a registered underwritten public offering.

The company granted the underwriter an option to buy up to $15 million of its common stock.

Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease, and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital and general corporate purposes.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.